For the quarter ended June 2025, AtriCure (ATRC Quick QuoteATRC - Free Report) reported revenue of $136.14 million, up 17.1% over the same period last year. EPS came in at -$0.02, compared to -$0.17 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $130.15 million, representing a surprise of +4.61%. The company delivered an EPS surprise of +86.67%, with the consensus EPS estimate being -$0.15.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how AtriCure performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• United States Revenue- Pain management: $21.17 million versus the three-analyst average estimate of $18.36 million. The reported number represents a year-over-year change of +41.1%.
• International Revenue- Pain management: $2.03 million compared to the $2.24 million average estimate based on three analysts. The reported number represents a change of +63.8% year over year.
• United States Revenue- Total ablation: $44.31 million versus the three-analyst average estimate of $62.64 million. The reported number represents a year-over-year change of -23.1%.
• International Revenue- Total ablation: $12.72 million versus the three-analyst average estimate of $14.37 million. The reported number represents a year-over-year change of +4.5%.
• United States Revenue- Total: $110.58 million versus the three-analyst average estimate of $105.65 million. The reported number represents a year-over-year change of +15.8%.
• International Revenue- Appendage management: $10.8 million compared to the $10.33 million average estimate based on three analysts. The reported number represents a change of +26.3% year over year.
• United States Revenue- Open ablation: $36.47 million versus $35.47 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +18.6% change.
• International Revenue- Open ablation: $10.35 million versus the three-analyst average estimate of $10.15 million. The reported number represents a year-over-year change of +12.9%.
• United States Revenue- Minimally invasive ablation: $7.84 million versus $8.81 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -33.7% change.
• International Revenue- Minimally invasive ablation: $2.37 million versus $1.98 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +34.5% change.
• United States Revenue- Appendage management: $45.11 million versus the three-analyst average estimate of $43.01 million. The reported number represents a year-over-year change of +18.9%.
• International Revenue- Total: $25.56 million versus the three-analyst average estimate of $24.69 million. The reported number represents a year-over-year change of +23.3%.

View all Key Company Metrics for AtriCure here>>>

Shares of AtriCure have returned +1.4% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.